Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Neoplasms 11Breast Neoplasms 8Prostatic Neoplasms 4Colorectal Neoplasms 4Polycystic Ovary Syndrome 3Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Pancreatic cancer, adult 2Ovarian Neoplasms 2Lymphoma 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Stroke 1Skin Neoplasms 1Sezary Syndrome 1Retroviridae Infections 1Renal Insufficiency 1Prostate Cancer Metastatic 1Pancreatic carcinoma, familial 1Pancreatic Neoplasms 1Ovarian Germ Cell Cancer 1Oligomenorrhea 1Obesity 1Non-alcoholic Fatty Liver Disease 1Neoplastic Cells, Circulating 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1

Interventions

Hematologic Tests 1Echocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dyspnea × Hematologic Tests × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡